Virta Health study. FDA-cleared algorithms. Arthritis DTx.

In this article:

This is the fifth edition of the E&O weekly newsletter for paying subscribers. Topics discussed include lessons from Theranos, Virta’s two-year study, FDA-cleared algorithms, DTx generics and more.

Issue 005. Virta Health study. FDA-cleared algorithms. Arthritis DTx.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 71 percent open rate. Here's what's happening this week:

Your editor is on cup 23 of 25 in an n=1 replication of this week's breakthrough study coffee consumption study.
Apple added menstrual cycle tracking and hearing health protection to the Apple Watch.
Samsung NEXT declared the end of the beginning of digital health.
Accenture's new 33-page report (pdf) on the state of digital health declares that "digital is no longer a differentiator."

Don't click those, read on for more important studies, deals, insights, frameworks, and news below.

Did this get forwarded to you? Not yet a paying subscriber? You can sign up right over here.

Virta's two-year study results

The big outcomes story this week goes

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Virta Health study. FDA-cleared algorithms. Arthritis DTx.

Welcome to E&O.

Virta's two-year study results

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.